RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Pliant Therapeutics Stocks 2024

Pliant Therapeutics Stocks

58.72 M

Pliant Therapeutics Dividend yield

Ticker

PLRX

ISIN

US7291391057

WKN

A2P4YV

In 2024, Pliant Therapeutics had 58.72 M outstanding stocks, a 0% change from the 58.72 M stocks in the previous year.

The Pliant Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e58.72
2028e58.72
2027e58.72
2026e58.72
2025e58.72
2024e58.72
202358.72
202242.02
202135.85
202021.34
201934.2
201834.2
201734.2

Pliant Therapeutics Aktienanalyse

What does Pliant Therapeutics do?

Pliant Therapeutics Inc is a biopharmaceutical company located in South San Francisco, California. The company was founded in 2016 by a group of scientists specializing in the discovery of therapeutics for the treatment of fibrosis and cancer. The history of Pliant Therapeutics Inc begins with the discovery of proteins involved in the development of fibrosis. These proteins, known as integrins, play a key role in tissue repair and regeneration. However, when they are overactive, they can lead to an overproduction of connective tissue, resulting in fibrosis. Pliant Therapeutics Inc aims to develop innovative therapeutics for the treatment of fibrosis and cancer. The company utilizes an innovative business model based on the discovery and development of novel therapeutics targeting the regulation of integrins. The company specializes in various areas. One important focus is the research of therapeutics for the treatment of lung diseases such as idiopathic pulmonary fibrosis (IPF) and asthma. Pliant Therapeutics Inc focuses on the discovery of drugs that inhibit the fibrosis process and improve lung function. Another focus of Pliant Therapeutics Inc is the development of therapeutics for the treatment of connective tissue disorders, such as scleroderma and systemic lupus erythematosus (SLE). The company has also launched a program for the development of therapeutics for the treatment of cancer. Pliant Therapeutics Inc focuses on the discovery of drugs that inhibit tumor growth and improve the effectiveness of cancer drugs. Pliant Therapeutics Inc has several products in the pipeline, including PT004 for the treatment of lung diseases and PT001 for the treatment of scleroderma. PT004 is an inhalable drug that aims to inhibit the fibrosis process in the lungs. It is currently in Phase 2 of clinical development and has the potential to improve lung function in patients with idiopathic pulmonary fibrosis (IPF) and severe asthma. PT001 is an orally administered drug that targets the treatment of scleroderma. The drug is currently in preclinical development and has the potential to inhibit the fibrosis process in various organs. Overall, Pliant Therapeutics Inc has the potential to play a leading role in the discovery and development of novel therapeutics for the treatment of fibrosis and cancer. The company is well-funded and has an experienced team of scientists and managers specializing in the development of innovative therapeutics. Pliant Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Pliant Therapeutics's Shares Outstanding

Pliant Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Pliant Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Pliant Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Pliant Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Pliant Therapeutics Stock

How many stocks are there of Pliant Therapeutics?

The current number of stocks of Pliant Therapeutics is 58.72 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Pliant Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Pliant Therapeutics evolved in recent years?

The number of shares of Pliant Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Pliant Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Pliant Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Pliant Therapeutics pay?

Over the past 12 months, Pliant Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pliant Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Pliant Therapeutics?

The current dividend yield of Pliant Therapeutics is .

When does Pliant Therapeutics pay dividends?

Pliant Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pliant Therapeutics?

Pliant Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Pliant Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pliant Therapeutics located?

Pliant Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pliant Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pliant Therapeutics from 6/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/3/2024.

When did Pliant Therapeutics pay the last dividend?

The last dividend was paid out on 6/3/2024.

What was the dividend of Pliant Therapeutics in the year 2023?

In the year 2023, Pliant Therapeutics distributed 0 USD as dividends.

In which currency does Pliant Therapeutics pay out the dividend?

The dividends of Pliant Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Pliant Therapeutics

Our stock analysis for Pliant Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pliant Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.